# IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

> **NCT05124795** · PHASE1 · TERMINATED · sponsor: **Immunic AG** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** IMU-935

## Key facts

- **NCT ID:** NCT05124795
- **Lead sponsor:** Immunic AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-09
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Lack of Efficacy
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05124795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05124795, "IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05124795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*